Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Pediatr Blood Cancer ; 63(7): 1181-4, 2016 07.
Article in English | MEDLINE | ID: mdl-27062362

ABSTRACT

BACKGROUND: Transient hyperglycemia (TH) represents an acknowledged adverse event that occurs during treatment in children with acute lymphoblastic leukemia (ALL) and has recently been associated with an increased risk for developing metabolic disturbances in future life. Our aim was to estimate the incidence of TH and to identify risk factors, thus serving as markers for identifying candidates for prevention interventions. PROCEDURE: All patients treated with induction treatment for ALL in our department from January 2004 to April 2015 had their data retrieved from medical files and retrospectively analyzed. RESULTS: One hundred and two children with ALL treated at our department were identified (49 females and 53 males) with a mean age of 6.03 ± 3.78 years at the time of diagnosis. Sixteen patients developed TH (15.68%). Age at diagnosis >10 years is associated with an 11-fold increase in the risk of developing TH. Additionally, fasting glucose on the eighth day of treatment is an important prognostic factor as fasting glucose >100 mg/dl at that time point is associated with a threefold increase in developing TH during residual treatment period. CONCLUSIONS: Fasting glucose levels >110 mg/dl on the eighth day of treatment could serve as a trigger for intervention strategies that will prevent the development of TH in pediatric patients treated for ALL. Additional studies are needed to confirm and further extend this preliminary observation.


Subject(s)
Asparaginase/adverse effects , Blood Glucose/metabolism , Hyperglycemia , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Adolescent , Asparaginase/administration & dosage , Child , Child, Preschool , Female , Humans , Hyperglycemia/blood , Hyperglycemia/chemically induced , Infant , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Retrospective Studies , Risk Factors
2.
Eur J Cancer ; 48(12): 1860-6, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22230747

ABSTRACT

An increase of the prevalence of childhood allergic diseases and the incidence of childhood Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL) were reported in the late 20th century. Among adults, several studies point to an inverse association with lymphoma; it remains to be confirmed whether allergy is also related to childhood lymphomas and whether the association, if any, is of an aetiologic nature. Between 1996 and 2008, 277 children (aged 0-14 years) with HL (N = 111) or NHL (N = 166) were enrolled in Nationwide Registry for Childhood Hematological Malignancies (NARECHEM), a Greek hospital-based-registry of childhood hematological malignancies. Hospital controls were individually matched to cases on age and sex. Multivariate conditional logistic regression was used to estimate odds ratios (ORs) with 95%confidence intervals (CIs) for associations of allergic diseases and other covariates with childhood HL or NHL risk. Subsequently, we combined our results with those of a French case-control study in a meta-analysis amounting to a total of 330 NHL cases/1478 controls and 239 HL cases/959 controls. After controlling for sociodemographic, perinatal and environmental factors, childhood NHL was less prevalent among children with allergy-associated symptoms overall (OR:0.50, 95%CI:0.27-0.92) or a history of asthma (OR:0.43, 95%CI:0.21-0.88). By contrast, allergy did not seem to be associated with childhood HL risk, although statistical power was limited. Fewer seaside holidays and higher birth weight were also associated with increased childhood NHL risk. The combined OR of the two studies for the association of asthma with NHL risk was: 0.52, 95%CI:0.32-0.84, whereas for HL: 0.86, 95%CI:0.51-1.45. Allergy seems to be strongly and inversely associated with childhood NHL. It remains to be elucidated in future investigations comprising larger populations, focusing on specific disease subtypes and employing more pertinent study-designs, whether this association is genuinely protective.


Subject(s)
Hodgkin Disease/complications , Hypersensitivity/complications , Lymphoma, Non-Hodgkin/complications , Case-Control Studies , Child , Child, Preschool , Female , Greece/epidemiology , Hodgkin Disease/epidemiology , Humans , Hypersensitivity/epidemiology , Lymphoma, Non-Hodgkin/epidemiology , Male
3.
Pediatr Blood Cancer ; 58(3): 344-51, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21990018

ABSTRACT

BACKGROUND: Maternal smoking during pregnancy has been often implicated in the development of childhood leukemia with ambiguous results. Hence, we conducted a meta-analysis aiming to summarize current evidence and quantify any tentative impact. PROCEDURE: We retrieved one cohort (553 leukemias compared to 1,440,542 children), 20 case-control studies and also analyzed the updated Greek case-control dataset with unpublished data, yielding in total 11,092 cases and 25,221 controls. RESULTS: Odds ratios reported in the studies included ranged from 0.70 to 2.20 for acute lymphocytic (ALL) and from 0.60 to 2.17 for acute myelocytic leukemia (AML). The combined effect regarding the association of maternal smoking (any vs. no) and leukemia risk was 1.03 for ALL (95% CI = 0.95-1.12, random effects model) and 0.99 for AML (95% CI = 0.90-1.09, fixed effects model). The results remained unchanged when sensitivity analyses were undertaken of studies reporting same maternal smoking periods, those focusing only on childhood leukemia deaths or investigations which did not clearly define AML subtype. CONCLUSIONS: The findings of the meta-analysis challenge the limits of traditional epidemiology to provide sound inferences when point estimates of constituent studies range around the null. In particular, this study provides no support to a hypothesis linking maternal smoking during pregnancy with subsequent development of main childhood leukemia subtypes. Further investigations employing molecular and genetic epidemiology, however, might be needed in the hope to reveal even minimal risks pertaining individuals with specific susceptibility to tobacco compounds who sustain high environmental exposures prenatally or postnatally.


Subject(s)
Leukemia, Myeloid, Acute/etiology , Prenatal Exposure Delayed Effects/etiology , Smoking/adverse effects , Adolescent , Case-Control Studies , Child , Child, Preschool , Female , Greece/epidemiology , Humans , Infant , Infant, Newborn , Leukemia, Myeloid, Acute/epidemiology , Male , Matched-Pair Analysis , Pregnancy , Prenatal Exposure Delayed Effects/epidemiology , Risk , Smoking/epidemiology
6.
Turk J Pediatr ; 48(2): 101-4, 2006.
Article in English | MEDLINE | ID: mdl-16848106

ABSTRACT

The aim of our study was to evaluate bone metabolism with measurement of bone mineral density (BMD) after management (chemo-, radiotherapy) for childhood acute lymphoblastic leukemia (ALL). Bone mineral density (g/cm2) of lumbar spine was measured by dual energy X-ray absorptiometry (Norland bone densitometer) in 18 children with ALL and a median of 34 months' post-diagnosis with no history of relapse, secondary malignancy, or transplantation. In addition, patients' BMDs were correlated with particular attention to age, sex and time (years) from completion of chemotherapy. The results were compared with healthy age- and sex-matched controls of the same population and expressed as standard deviation scores (SDS). Mean age of children was 9.8 +/- 3.7 years. Of 18 children (10 boys and 8 girls), 13 were grouped as standard and 5 as high-risk, respectively. Based on z-score values, 9 were classified as normal (z-score <1 SD), 7 as osteopenic (z-score 1-2.5 SD) and 2 as osteoporotic (z-score >2.5 SD). Children with ALL had reduced lumbar BMDs (z score -0.99) in comparison to healthy controls (z score -0.14) (p=0.011), which is indicative of relative osteopenia. Moreover, the reduced BMD was associated with patient age (z score -0.14 and -1.52 for ages <10 and >10 years, respectively, p=0.016). Reduced BMD was not correlated with time from completion of chemotherapy (p=0.33), risk group (p=0.9) and sex (p=0.3). We conclude that children's BMDs are reduced after completion of chemotherapy for ALL. The causes are multifactorial and mainly related to antineoplastic treatments, such as corticosteroids and methotrexate, physical inactivity and cranial irradiation. We suggest that further studies are needed to evaluate the long-term effect on BMD in these children and to prevent pathological fractures later in life.


Subject(s)
Antineoplastic Agents/adverse effects , Bone Diseases, Metabolic/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Absorptiometry, Photon , Bone Density , Bone Diseases, Metabolic/diagnostic imaging , Case-Control Studies , Child , Female , Humans , Lumbar Vertebrae/diagnostic imaging , Male , Osteoporosis/diagnostic imaging , Osteoporosis/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Survivors
7.
Pediatr Hematol Oncol ; 22(4): 285-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16020115

ABSTRACT

Osteopenia and osteoporosis are currently receiving particular attention as late effects of therapy in survivors of childhood acute lymphoblastic leukemia (ALL). The aim of this study was to evaluate abnormalities in bone mass and mineral homeostasis in children with ALL after induction therapy (during consolidation treatment). Lumbar spine (L2-L4) bone mineral density (BMD, g/cm(2)) was measured by dual energy X-ray absorptiometry in 20 children with ALL, a median of 25.9 months postdiagnosis and results were expressed as z-scores relative to healthy Caucasian children (controls). Serum levels of intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), calcium, phosphate, and magnesium were also analyzed. In addition, the body mass indexes (kg/cm(2)) of patients and controls were calculated. Results were compared with those of 40 healthy controls. Among the 20 children with ALL (12 boys and 8 girls), 12 presented z-scores < 1 SD (normal) and 8 were osteopenic (z-score between 1 and 2.5 SD). In addition, children with ALL had reduced lumbar BMDs (z-score -0.817) in comparison to healthy controls (z-score -0.353) (p = .04). Moreover, alkaline phosphatase and intact parathyroid hormone values were significantly increased compared to controls values. The data demonstrate that bone metabolism in children with ALL during consolidation therapy is disturbed, resulting in a reduced BMD and z-score with respect to healthy controls. Since a reduced BMD predisposes to osteopenia and osteoporosis, specific attention and therapeutic interventions should be considered.


Subject(s)
Bone Diseases, Metabolic/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Absorptiometry, Photon , Adolescent , Antineoplastic Agents/therapeutic use , Biomarkers/blood , Body Mass Index , Bone Density , Bone Diseases, Metabolic/diagnosis , Case-Control Studies , Child , Child, Preschool , Female , Humans , Lumbar Vertebrae/physiopathology , Male , Osteoporosis/diagnosis , Osteoporosis/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Prospective Studies , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL
...